Fig. 1

Survival analysis. Tacrolimus remarkably prolonged both WAT and SAT group survivals (p < 0.01, compared with WA and SA), but there was still significant difference between WAT and SAT p = 0.047). Compared to the SAT group, mean survival time was much longer than that in SATa group (p = 0.331). 28-day cumulative survival rates (85.7%) of WAT group were higher than SAT group (28.6%) (P = 0.019, log-rank test). The survival rate (51.7%) of SATa is higher than SAT group (P = 0.266, log-rank test). whole size allografrs (WA), small-for-size allograft (SA), whole size allografrs+Tac (WAT), small-for-size allograft+Tac (SAT), small-for-size allograft+Tac altered dose (SATa)